ライフサイエンスコーパス: non-insulin-dependent

1 Non-insulin dependent diabetes mellitus (NIDDM) affects

2 opment of several chronic diseases including non-insulin dependent diabetes mellitus (NIDDM) and coro

3 and fetal thinness have been associated with non-insulin dependent diabetes mellitus (NIDDM) and insu

4 tudy tested the hypothesis that persons with non-insulin dependent diabetes mellitus (NIDDM) have gre

5 ales) suffering from periodontal disease and non-insulin dependent diabetes mellitus (NIDDM) were ran

6 pedigrees ascertained through siblings with non-insulin dependent diabetes mellitus (NIDDM).

7 (GK) rats are a well characterized model for non-insulin dependent diabetes mellitus (NIDDM).

8 olic homeostasis associated with obesity and non-insulin dependent diabetes mellitus (NIDDM).

9 lin-dependent diabetes mellitus (type 1) and non-insulin dependent diabetes mellitus (type 2) after l

10 lase (GADA) can occur in apparently typical, non-insulin dependent diabetes mellitus (type 2).

11 hile it is well established that people with non-insulin dependent diabetes mellitus have defects in

12 e hypothesis that endothelial dysfunction in non-insulin dependent diabetes mellitus is the consequen

13 Its occurrence in non-insulin dependent diabetes mellitus is well supporte

14 Non-insulin dependent diabetes mellitus results in diver

15 had comparable defects in glucose clearance, non-insulin dependent diabetes mellitus subjects also ha

16 Therefore, nondiabetic (lean and obese) and non-insulin dependent diabetes mellitus subjects were st

17 Insulin resistance, the hallmark of non-insulin dependent diabetes mellitus, is characterize

18 the presence of enhanced oxidative stress in non-insulin dependent diabetes mellitus, with recent dat

19 ing cause of both morbidity and mortality in non-insulin dependent diabetes mellitus.

20 h may reduce the risk of vascular disease in non-insulin dependent diabetes mellitus.

21 , hypertension, coronary-artery disease, and non-insulin-dependent diabetes (NIDDM).

22 areas of interest are the acute treatment of non-insulin-dependent diabetes (type 2), the management

23 Hepatic steatosis is common in non-insulin-dependent diabetes and can be associated wit

24 Coronary heart disease, hypertension, non-insulin-dependent diabetes and obesity are major cau

25 tant therapeutic target for the treatment of non-insulin-dependent diabetes and possibly obesity, bas

26 with impaired glucose tolerance, and 26 with non-insulin-dependent diabetes by World Health Organizat

27 dds ratio, 11.2; P = 0.04), and 6 of 43 with non-insulin-dependent diabetes mellitus (14%; odds ratio

28 m the Finland-United States Investigation of Non-Insulin-Dependent Diabetes Mellitus (FUSION) Genetic

29 m the Finland-United States Investigation of Non-Insulin-Dependent Diabetes Mellitus (FUSION) study.

30 r an autosomal dominant, early-onset form of non-insulin-dependent diabetes mellitus (maturity-onset

31 tropical calcific pancreatitis (n = 15), and non-insulin-dependent diabetes mellitus (n = 43) and con

32 Recent evidence suggests that non-insulin-dependent diabetes mellitus (NIDDM) and card

33 We investigated whether risk for non-insulin-dependent diabetes mellitus (NIDDM) and meta

34 ew the effect of weight on the prevalence of non-insulin-dependent diabetes mellitus (NIDDM) and of i

35 controls and obese subjects with or without non-insulin-dependent diabetes mellitus (NIDDM) during n

36 Patients with non-insulin-dependent diabetes mellitus (NIDDM) exhibit

37 ontributing to postprandial hyperglycemia in non-insulin-dependent diabetes mellitus (NIDDM) has not

38 First-degree relatives of patients with non-insulin-dependent diabetes mellitus (NIDDM) have an

39 s of the pathophysiology of renal disease in non-insulin-dependent diabetes mellitus (NIDDM) have bee

40 andidate responsible for the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM) in human

41 ompound troglitazone, which is used to treat non-insulin-dependent diabetes mellitus (NIDDM) in man,

42 tle, if any, impact on the long-term risk of non-insulin-dependent diabetes mellitus (NIDDM) in the g

43 Care of persons with non-insulin-dependent diabetes mellitus (NIDDM) in the U

44 is that severe periodontitis in persons with non-insulin-dependent diabetes mellitus (NIDDM) increase

45 Non-insulin-dependent diabetes mellitus (NIDDM) is a maj

46 Non-insulin-dependent diabetes mellitus (NIDDM) is a mul

47 The islet in non-insulin-dependent diabetes mellitus (NIDDM) is chara

48 Susceptibility to non-insulin-dependent diabetes mellitus (NIDDM) is large

49 resistance in the offspring of parents with non-insulin-dependent diabetes mellitus (NIDDM) is the b

50 Type 2 or non-insulin-dependent diabetes mellitus (NIDDM) is the m

51 Non-insulin-dependent diabetes mellitus (NIDDM) may caus

52 Hypertension is a common finding in non-insulin-dependent diabetes mellitus (NIDDM) nephropa

53 ivity remains impaired in skeletal muscle of non-insulin-dependent diabetes mellitus (NIDDM) patients

54 measure of insulin sensitivity in studies of non-insulin-dependent diabetes mellitus (NIDDM) risk, bu

55 Control rats and those with non-insulin-dependent diabetes mellitus (NIDDM) underwen

56 gated the role of MIF in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM) using MI

57 iabetes mellitus (IDDM) and 15 patients with non-insulin-dependent diabetes mellitus (NIDDM) were mat

58 sulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) were ran

59 abetes mellitus ($1996 per QALY), those with non-insulin-dependent diabetes mellitus (NIDDM) who use

60 R was 5.4 micrograms/minute for persons with non-insulin-dependent diabetes mellitus (NIDDM) who were

61 al placebo regimen in over 600 patients with non-insulin-dependent diabetes mellitus (NIDDM) who were

62 pendent diabetes mellitus, 26% of those with non-insulin-dependent diabetes mellitus (NIDDM) who were

63 isposal is a common finding in patients with non-insulin-dependent diabetes mellitus (NIDDM), as well

64 sensitivity in obesity and in patients with non-insulin-dependent diabetes mellitus (NIDDM), by acti

65 orted positive result from a genome scan for non-insulin-dependent diabetes mellitus (NIDDM), Hanis e

66 g schizophrenia, bipolar affective disorder, non-insulin-dependent diabetes mellitus (NIDDM), inflamm

67 insulin resistance have been associated with non-insulin-dependent diabetes mellitus (NIDDM), obesity

68 th insulin resistance syndrome (IRS) such as non-insulin-dependent diabetes mellitus (NIDDM), obesity

69 s (18 to 97 years of age) with hypertension, non-insulin-dependent diabetes mellitus (NIDDM), recent

70 on and carries a high risk for conversion to non-insulin-dependent diabetes mellitus (NIDDM).

71 bout infant-feeding practices and subsequent non-insulin-dependent diabetes mellitus (NIDDM).

72 Obesity is an established risk factor for non-insulin-dependent diabetes mellitus (NIDDM).

73 rt and liver similar to those of humans with non-insulin-dependent diabetes mellitus (NIDDM).

74 in-resistant subjects at risk for developing non-insulin-dependent diabetes mellitus (NIDDM).

75 d facilitate improved care for patients with non-insulin-dependent diabetes mellitus (NIDDM).

76 redisposition factors for the development of non-insulin-dependent diabetes mellitus (NIDDM).

77 search questions about metabolic control and non-insulin-dependent diabetes mellitus (NIDDM).

78 Tarui disease and conceivably contributes to non-insulin-dependent diabetes mellitus (NIDDM).

79 esistant subjects (OB), and in subjects with non-insulin-dependent diabetes mellitus (NIDDM).

80 ls have been advocated for the management of non-insulin-dependent diabetes mellitus (NIDDM).

81 of morbidity and mortality in patients with non-insulin-dependent diabetes mellitus (NIDDM).

82 y underlie insulin resistance in obesity and non-insulin-dependent diabetes mellitus (NIDDM).

83 are insulin sensitizers in rodent models of non-insulin-dependent diabetes mellitus (NIDDM).

84 vely from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM).

85 vely from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM).

86 ouse strain is a newly established model for non-insulin-dependent diabetes mellitus (NIDDM).

87 reminiscent of both Laron-type dwarfism and non-insulin-dependent diabetes mellitus (NIDDM).

88 red insulin secretion is a characteristic of non-insulin-dependent diabetes mellitus (NIDDM).

89 been proved to be caused by mtDNA mutations; non-insulin-dependent diabetes mellitus (NIDDM); and hyp

90 rearm resistance vessels of 21 patients with non-insulin-dependent diabetes mellitus and 23 matched h

91 s associated with greatly increased risks of non-insulin-dependent diabetes mellitus and cardiovascul

92 s are a characteristic pathologic feature of non-insulin-dependent diabetes mellitus and contain isle

93 resistant (IR) offspring of individuals with non-insulin-dependent diabetes mellitus and eight age-we

94 dence of such complications in patients with non-insulin-dependent diabetes mellitus and hypertension

95 n important adjunct in the treatment of both non-insulin-dependent diabetes mellitus and insulin-depe

96 aired in patients with insulin-dependent and non-insulin-dependent diabetes mellitus and restored by

97 ortunity to screen the gene in patients with non-insulin-dependent diabetes mellitus and/or obesity f

98 Insulin resistance and non-insulin-dependent diabetes mellitus are major causes

99 obesity, hypertension, hyperlipidaemia, and non-insulin-dependent diabetes mellitus are set against

100 ng individuals already at increased risk for non-insulin-dependent diabetes mellitus because of obesi

101 forearm resistance vessels of patients with non-insulin-dependent diabetes mellitus can be improved

102 nset diabetes of the young (MODY), a form of non-insulin-dependent diabetes mellitus characterized by

103 m the Finland-United States Investigation of Non-Insulin-Dependent Diabetes Mellitus Genetics study a

104 eting exercise, IR offspring of parents with non-insulin-dependent diabetes mellitus had (i) normal r

105 to improve insulin resistance in obesity and non-insulin-dependent diabetes mellitus in both rodents

106 nvestigation of agouti's role in obesity and non-insulin-dependent diabetes mellitus in mice holds si

107 y be critical in the long-term management of non-insulin-dependent diabetes mellitus in obese patient

108 .1 region linked with insulin resistance and non-insulin-dependent diabetes mellitus in the Pima Indi

109 hepatic glucose production in obesity and/or non-insulin-dependent diabetes mellitus may reflect resi

110 ed with a reduced dementia risk in initially non-insulin-dependent diabetes mellitus patients.

111 cept natives of Alaska, have a prevalence of non-insulin-dependent diabetes mellitus that is two to s

112 hts (lean to very obese) and with or without non-insulin-dependent diabetes mellitus to examine the r

113 ent with mixed connective tissue disease and non-insulin-dependent diabetes mellitus who developed an

114 may portend an increase in the incidence of non-insulin-dependent diabetes mellitus with important p

115 tify the genetic basis for susceptibility to non-insulin-dependent diabetes mellitus within the conte

116 s have suggested linkage of Type 2 diabetes (non-insulin-dependent diabetes mellitus) susceptibility

117 ated in a model of type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), the ob/ob mous

118 n in 49 men (26 without diabetes and 23 with non-insulin-dependent diabetes mellitus).

119 ncidence of adult hypertension, incidence of non-insulin-dependent diabetes mellitus, and prevalence

120 disease that accompanies obesity and related non-insulin-dependent diabetes mellitus, and that the ad

121 nsorineural hearing loss, childhood obesity, non-insulin-dependent diabetes mellitus, hyperlipidemia

122 Obesity, non-insulin-dependent diabetes mellitus, hypertension, c

123 d with increased risk of type 2 diabetes, or non-insulin-dependent diabetes mellitus, in Mexican Amer

124 he abnormalities associated with early stage non-insulin-dependent diabetes mellitus, including gluco

125 x1 gene are linked to an early onset form of non-insulin-dependent diabetes mellitus, MODY-4.

126 the development of one form of early-onset, non-insulin-dependent diabetes mellitus, MODY1, as well

127 ective in the treatment of type II diabetes (non-insulin-dependent diabetes mellitus, NIDDM).

128 d to diseases with late age at onset such as non-insulin-dependent diabetes mellitus, psychiatric dis

129 ith islets from rodent models of obesity and non-insulin-dependent diabetes mellitus, suggesting the

130 nge affect the risk for diabetes, especially non-insulin-dependent diabetes mellitus, the authors exa

131 At the onset of non-insulin-dependent diabetes mellitus, the islets from

132 pancreatic diseases in Bangladesh, including non-insulin-dependent diabetes mellitus, was undertaken.

133 condition similar to adult-onset obesity and non-insulin-dependent diabetes mellitus.

134 ole in the insulin resistance of obesity and non-insulin-dependent diabetes mellitus.

135 e production characteristic of patients with non-insulin-dependent diabetes mellitus.

136 ms, and its levels are increased in serum in non-insulin-dependent diabetes mellitus.

137 non-full sibs in a genetic linkage study of non-insulin-dependent diabetes mellitus.

138 sion may be modulated in disease states like non-insulin-dependent diabetes mellitus.

139 dividuals with impaired glucose tolerance or non-insulin-dependent diabetes mellitus.

140 esistance and is the biggest risk factor for non-insulin-dependent diabetes mellitus.

141 ionship of ob gene expression to obesity and non-insulin-dependent diabetes mellitus.

142 c oxide-mediated vasodilation is impaired in non-insulin-dependent diabetes mellitus.

143 riants of IRS-1, especially in patients with non-insulin-dependent diabetes mellitus.

144 etic (ZDF/Gmifa) rats were used as models of non-insulin-dependent diabetes mellitus.

145 with IIP and MDI is effective in controlling non-insulin-dependent diabetes mellitus.

146 have been proposed as a potential cause for non-insulin-dependent diabetes mellitus.

147 forearm resistance vessels of patients with non-insulin-dependent diabetes mellitus.

148 role of islet amyloid in the pathogenesis of non-insulin-dependent diabetes mellitus.

149 b gene in these animal models of obesity and non-insulin-dependent diabetes mellitus.

150 hyperglycemia in both insulin-dependent and non-insulin-dependent diabetes mellitus.

151 ed vasodilation is abnormal in patients with non-insulin-dependent diabetes mellitus.

152 contribute to the insulin resistance seen in non-insulin-dependent diabetes mellitus.

153 as are a class of drugs widely used to treat non-insulin-dependent diabetes mellitus.

154 ay be useful in the treatment of obesity and non-insulin-dependent diabetes mellitus.

155 death for any MPS result than patients with non-insulin-dependent diabetes mellitus.

156 iabetes, tropical calcific pancreatitis, and non-insulin-dependent diabetes mellitus.

157 of obesity, including insulin resistance and non-insulin-dependent diabetes mellitus.

158 the insulin resistance syndrome and risk of non-insulin-dependent diabetes mellitus.

159 hibits a phenotype that includes obesity and non-insulin-dependent diabetes mellitus.

160 to the most common complication of obesity, non-insulin-dependent diabetes mellitus.

161 significantly reduce the risk of developing non-insulin-dependent diabetes mellitus.

162 o the impaired insulin secretion observed in non-insulin-dependent diabetes mellitus.

163 del of the insulin resistance of obesity and non-insulin-dependent diabetes mellitus.

164 an important role in the pathophysiology of non-insulin-dependent diabetes mellitus.

165 -HD genes result in genetic diseases such as non-insulin-dependent diabetes mellitus.

166 troglitazone (TRO) was used for treatment of non-insulin-dependent diabetes until its removal from th

167 both fractions from the obese subjects with non-insulin-dependent diabetes was significantly decreas

168 by focusing on type-2 diabetes (adult-onset non-insulin-dependent diabetes)--an increasingly prevale

169 in, degree of physical function, presence of non-insulin-dependent diabetes, and cardiovascular risk

170 pplications to the genetics of hypertension, non-insulin-dependent diabetes, and obesity.

171 the study of diseases of late onset, such as non-insulin-dependent diabetes, cardiovascular diseases,

172 fed with high-fat diet (HFD) that developed non-insulin-dependent diabetes, two episodes of systemic

173 e later propensity to insulin resistance and non-insulin-dependent diabetes, whereas slow growth as a

174 that could become beneficial in controlling non-insulin-dependent diabetes.

175 nti-hyperglycemic drugs for the treatment of non-insulin-dependent diabetes.

176 iabetic subjects, and obese individuals with non-insulin-dependent diabetes.

177 s result in profound obesity and symptoms of non-insulin-dependent diabetes.

178 and provides a genetically amenable model of non-insulin-dependent diabetes.

179 mental factors contribute to the etiology of non-insulin-dependent diabetes.

180 gulation of glucose metabolism is altered in non-insulin-dependent diabetes.

181 17 nondiabetic control and 13 subjects with non-insulin-dependent diabetes.

182 ent both the onset of obesity and associated non-insulin-dependent diabetes.

183 postprandial hyperglycemia are hallmarks of non-insulin-dependent diabetes.

184 pstairs; 4.5 (2.5-7.8) and 3.8 (1.9-7.3) for non-insulin-dependent diabetes; and 4.2 (3.6-5.0) and 2.

185 e-diabetic people; halving the prevalence of non-insulin-dependent diabetes; and complete cessation o

186 ority of subjects with diabetes have type 2 (non-insulin dependent) diabetes.

187 Type 2 (non-insulin-dependent) diabetes is associated with a mar

188 Type-II (non-insulin-dependent) diabetes mellitus (NIDDM) is a he

189 vascular morphology and function in type 2 (non-insulin-dependent) diabetes mellitus (type 2D), smal

190 Type I (insulin-dependent) and type II (non-insulin-dependent) diabetes mellitus are different d

191 both type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus, including isle

192 for type I (insulin-dependent) and type II (non-insulin-dependent) diabetes mellitus.

193 tes may influence the development of type 2 (non-insulin-dependent) diabetes, for example, through ef

194 ternal excess in the transmission of type 2 (non-insulin-dependent) diabetes.

195 decreases nonfasted blood glucose in obese, non-insulin-dependent diabetic C57BLKS-Lepr(db)/lepr(db)

196 healthy men (aged 50.4+/-9.6 years) and in 8 non-insulin-dependent diabetic men (aged 52.0+/-7.2 year

197 g; diastolic BP, <90 mm Hg) at baseline, 583 non-insulin-dependent diabetic patients and 4149 nondiab

198 ake on fish-oil treatment in 15 free-living, non-insulin-dependent diabetic patients was evaluated by

199 leptin and exhibits both an obese and a mild non-insulin-dependent diabetic phenotype.

200 a sample of 60 adults, including healthy and non-insulin-dependent diabetic subjects of either gender

201 pathway is responsible for hyperglycemia in non-insulin-dependent diabetics.

202 Non-insulin-dependent DM has independent adverse cardiac

203 nce, a proximal cause of Type II diabetes [a non-insulin dependent form of diabetes mellitus (NIDDM)]

204 rched using terms such as diabetes mellitus, non-insulin-dependent, hyperglycemia, prevalence, epidem

205 cose uptake in neuronal tissues is primarily non-insulin dependent, proteins involved in insulin sign

206 Ninety-eight adult participants with non-insulin-dependent type 2 diabetes who were diagnosed

207 acebo in 350 patients with poorly controlled non-insulin-dependent (type 2) diabetes mellitus (glycos

208 When subjects with non-insulin-dependent (type 2) diabetes mellitus (n = 11

209 Non-insulin-dependent (type 2) diabetes mellitus (NIDDM)

210 The disease non-insulin-dependent (type 2) diabetes mellitus (NIDDM)

211 genetically heterogeneous monogenic form of non-insulin-dependent (type 2) diabetes mellitus (NIDDM)

212 In prospective studies on non-insulin-dependent (type 2) diabetes mellitus patient

213 ination therapy is logical for patients with non-insulin-dependent (type 2) diabetes mellitus, becaus

214 Non-insulin-dependent (type II) diabetes has a strong fa

215 Non-insulin-dependent (type II) diabetes mellitus (NIDDM

216 agonists for evaluation in the treatment of non-insulin-dependent (type II) diabetes mellitus (NIDDM

217 ed morbidity and mortality, in patients with non-insulin-dependent (type II) diabetes mellitus, one c

218 aucasian offspring (mean age, 15.3 years) of non-insulin-dependent (type II) diabetics (n = 25) and n